News

HIV positive and negative patients with lymphoma as a predictor of outcome and tumour proliferation

12 Jan 2021
HIV positive and negative patients with lymphoma as a predictor of outcome and tumour proliferation

This authors of a new paper published in Oncotarget reported that the aim of this study is to investigate the correlation between ADC parameters, Ki-67 expression, overall survival and progression free survival in primary central nervous system lymphoma.

Their hypothesis is that ADC values will inversely correlate with Ki-67 expression and that tumours with higher ADC values above the median will have improved OS and PFS

Selection criteria yielded 90 patients, 23 patients living with HIV (positive and negative) and 67 immunocompetent patients.

In patients with available Ki-67 expression data, nADCmean, nADC15 and nADC75 inversely correlated with Ki-67 expression.

For PLWH, there was no correlation between ADC parameters and Ki-67 expression or clinical outcomes.

ADC histogram analysis can predict tumour proliferation and survival in immunocompetent patients with PCNSL, but with limited utility in PLWH.

Dr. Bilal Khan from The Baylor College of Medicine said, "Primary central nervous system lymphoma (PCNSL) is a rare subgroup of non-Hodgkin lymphoma confined to the central nervous system, with more than 90% of cases classified as Diffuse Large B-cell Lymphoma."

Diffusion weighted imaging and corresponding apparent diffusion coefficient maps can provide a representation of the cellular microenvironment with several studies demonstrating that ADC values can predict tumour cellularity across various neoplasms, including lymphomas.

In a recent similar study of whole tumour histogram analysis in PCNSL performed by the authors of this study, multiple ADC parameters were inversely correlated with Ki-67 expression and associated with poorer OS.

However, tumour segmentation was performed using only the ADC sequence with the potential inclusion of intra-tumoural necrosis, haemorrhage or regions outside of the actual solid tumour that would otherwise have been excluded with contrast co-registration, ultimately providing a suboptimal representation of true tumour parenchyma.

The primary aim of this study is to more comprehensively evaluate the relationship between ADC calculations with tumour Ki-67 expression and clinical outcomes using a larger patient sample with the inclusion of PLWH and whole tumour segmentation with T1 post contrast co-registration.

The Oncotarget author's hypothesis is that ADC values will inversely correlate with Ki-67 expression and that tumours with higher ADC values above the median will have improved OS and PFS.

The Khan Research Team concluded in their Oncotarget Research Paper that the role of MR in PCNSL historically has been the detection and qualitative evaluation of response to treatment.

DWI and derived ADC maps have been a well-established tool in neuroimaging, but the use of ADC histogram profiling has not been widely accepted in daily practice.

This data expands the role of conventional MR imaging by utilising quantitative ADC histogram analysis to predict clinical outcomes and tumour expression of Ki-67, a biomarker for tumour proliferative activity, in immunocompetent PCNSL patients.

The role of using ADC as an imaging biomarker in PLWH may be limited.

Quantitative ADC histogram analysis should be strongly considered as part of the imaging protocol in the evaluation of immunocompetent patients with PCNSL.

Source: Oncotarget